Giudice, Elena
 Distribuzione geografica
Continente #
NA - Nord America 143
EU - Europa 93
AS - Asia 83
AF - Africa 1
Totale 320
Nazione #
US - Stati Uniti d'America 142
SG - Singapore 46
IT - Italia 34
CN - Cina 17
IE - Irlanda 17
ID - Indonesia 13
SE - Svezia 9
FR - Francia 6
RU - Federazione Russa 5
DE - Germania 4
FI - Finlandia 4
KR - Corea 4
ES - Italia 3
GB - Regno Unito 3
NL - Olanda 3
CZ - Repubblica Ceca 2
AT - Austria 1
CA - Canada 1
CI - Costa d'Avorio 1
HU - Ungheria 1
IN - India 1
IR - Iran 1
JP - Giappone 1
LT - Lituania 1
Totale 320
Città #
Singapore 36
Ashburn 32
Chandler 27
Dublin 17
Jakarta 13
Rome 10
New York 8
San Mateo 6
Washington 6
Moscow 5
Beijing 4
Milan 4
Munich 4
New Haven 4
Amsterdam 3
Asti 3
Boston 3
Busto Arsizio 3
Helsinki 3
Jeju City 3
Marseille 3
Princeton 3
Bari 2
Guidonia Montecelio 2
Nave 2
Olomouc 2
Osimo 2
Pamplona 2
Paris 2
Abidjan 1
Andover 1
Antwerp 1
Budapest 1
Cambridge 1
Edgerton 1
Lappeenranta 1
Leawood 1
Los Angeles 1
Madrid 1
Mountain View 1
Norwalk 1
Redwood City 1
Santa Clara 1
Suyeong-gu 1
Tappahannock 1
Tokyo 1
Toronto 1
Vienna 1
York 1
Zanjan 1
Totale 235
Nome #
Pembrolizumab for advanced cervical cancer: safety and efficacy 42
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 42
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 37
PARP Inhibitors Resistance: Mechanisms and Perspectives 31
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond 31
Recent progress in the use of pharmacotherapy for endometrial cancer 28
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 26
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 22
Advanced and recurrent endometrial cancer: State of the art and future perspectives 21
Management of stage III and IVa uterine cancer 19
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 16
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 12
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience 9
Totale 336
Categoria #
all - tutte 2.601
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.601


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 1 0 0 0 1 0
2021/202225 0 0 0 5 0 0 1 7 2 1 2 7
2022/202384 6 9 2 9 2 8 4 3 6 9 19 7
2023/2024157 4 25 17 16 4 21 19 3 5 5 18 20
2024/202568 8 4 31 6 19 0 0 0 0 0 0 0
Totale 336